

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number
WO 2005/058873 A1


- (51) International Patent Classification⁷: **C07D 401/14**,
A61K 31/4184, C07D 417/14, A61P 11/00, 31/12
- (21) International Application Number:
PCT/EP2004/053606
- (22) International Filing Date:
20 December 2004 (20.12.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
03104802.8 18 December 2003 (18.12.2003) EP
60/566,835 30 April 2004 (30.04.2004) US
- (71) Applicant (for all designated States except US): **TIBOTEC PHARMACEUTICALS LTD.** [IE/IE]; Little Island, Co Cork (IE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BONFANTI, Jean-François** [FR/FR]; 4 bis Route Nationale, F-27430 André (FR). **ANDRIES, Koenraad, Jozef, Lodewijk** [BE/BE]; Oosteneinde 9, B-2340 Beerse (BE). **JANSSENS, Frans, Eduard** [BE/BE]; Tinststraat 79, B-2820 Bonheiden (BE). **SOMMEN, François, Maria** [BE/BE]; Langenberg 49, B-2323 Wortel (BE). **GUILLEMONT, Jérôme, Emile, Georges** [FR/FR]; 51bis, route de Muids, F-27430 André (FR). **LACRAMPE, Jean, Fernand, Armand** [FR/FR]; 15, chemin du Pont de l'Arche, F-76240 Le Mesnil-Esnard (FR).
- (74) Agent: **WANTE, Dirk**; Tibotec-Virco Comm. VA, Generaal De Wittelaan L 11B 3, B-2800 Mechelen (BE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ,

[Continued on next page]

(54) Title: **PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION**



(I)

(57) Abstract: The present invention concerns piperidine-amino-benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula (I) their prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms wherein Q is C₁₋₆alkyl optionally substituted with trifluoromethyl, C₃₋₇cycloalkyl, Ar², hydroxy, C₁₋₄alkoxy, C₁₋₄alkylthio, Ar²-oxy-, Ar²-thio-, Ar²(CH₂)_noxy, Ar²(CH₂)_nthio, hydroxycarbonyl, aminocarbonyl, C₁₋₄alkylcarbonyl, Ar²carbonyl, C₁₋₄alkoxycarbonyl, Ar²(CH₂)_ncarbonyl, aminocarbonyloxy, C₁₋₄alkylcarbonyloxy, Ar²carbonyloxy, Ar²(CH₂)_ncarbonyloxy, C₁₋₄alkoxy carbonyl(CH₂)_noxy, mono- or di(C₁₋₄alkyl)aminocarbonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl, mono- or di(C₁₋₄alkyl)aminosulfonyl or a heterocycles selected from the group consisting of pyrrolidinyl, pyrrolyl, dihydropyrrolyl, imidazolyl, triazolyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, pyridyl and tetrahydropyridyl, wherein each of said heterocycle may optionally be substituted with oxo or C₁₋₄alkyl; G is a direct bond or optionally substituted C₁₋₁₀lokanediyl; R¹ is Ar¹ or a monocyclic or bicyclic heterocycle; one of R^{2a} and R^{3a} is C₁₋₆alkyl and the other one of R^{2a} and R^{3a} is hydrogen; in case R^{2a} is different from hydrogen then R^{2b} is hydrogen or C₁₋₄alkyl, and R^{3b} is hydrogen; in case R^{3a} is different from hydrogen then R^{3b} is hydrogen or C₁₋₄alkyl, and R^{2b} is hydrogen; t is 1, 2 or 3; Ar¹ is phenyl or substituted phenyl; and Ar² is phenyl or substituted phenyl. It further concerns their preparation and compositions comprising them, as well as their use as a medicine.



NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.